氨溴索辅助治疗重症肺炎疗效观察

Observation on the therapeutic efficacy of Ambroxol in patients with severe pneumonia

目的 探讨静脉滴注氨溴索辅助治疗对重症肺炎患者病情改善的效果,以期为临床决策的制定提供参考。方法 选取联勤保障部队第九八九医院2019年5月—2021年5月收治的重症肺炎患者88例作为研究对象,采用随机数字表法将研究对象分为对照组和观察组,每组44例。2组患者入院后均接受重症肺炎常规治疗和护理,观察组患者在此基础上给予盐酸氨溴索治疗。比较2组患者的治疗总有效率和症状/体征改善时间,同时比较2组患者治疗前后的肺功能指标和血清炎症因子表达水平。结果 观察组患者的治疗总有效率为88.64%,高于对照组的70.45%(P<0.05)。观察组患者的咳嗽咳痰消失时间、体温恢复正常时间、肺部X片好转时间及肺部啰音消失时间等均明显短于对照组,差异均有统计学意义(P<0.05)。治疗前,2组患者的第1秒用力呼气量占用力肺活量的比值(FEV1/FVC)、FVC及呼气峰流速(PEF)等肺功能指标水平比较,差异均无统计学意义(P>0.05);治疗后,2组患者的FEV1/FVC、FVC及PEF水平均高于治疗前,且观察组明显高于对照组,差异均有统计学意义(P<0.05)。治疗前,2组患者的血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)及超敏C反应蛋白(hs-CRP)水平比较,差异均无统计学意义(P>0.05);治疗后,2组患者的血清TNF-α、IL-6及hs-CRP水平均低于治疗前,且观察组明显低于对照组,差异均有统计学意义(P<0.05)。结论 静脉滴注氨溴索辅助治疗能明显改善重症肺炎患者的肺功能,减轻症状,抑制机体炎症反应,值得临床推广。

Objective This paper aims to explore the effect of intravenous infusion of Ambroxol in improving the treatment of severe pneumonia to provide support for clinical decision-making.Methods A total of 88 patients with severe pneumonia admitted to the 989 Hospital of the Joint Logistics Support Force from May 2019 to May 2021 were selected as the study participants.They were randomly assigned to a control group(n=44)and an observation group(n=44)using a random number table.Both groups received routine treatment and nursing for severe pneumonia after admission,while the observation group was given Ambroxol treatment on this basis.The overall response rate of treatment and the improvement time of symptoms/signs of the two groups were compared.Moreover,the pulmonary function indicators and serum inflammatory factor expression levels before and after treatment were compared.Results The overall response rate of treatment in the observation group was 88.64%,which was significantly higher than that of the control group(70.45%;P<0.05).The time for disappearance of cough,sputum,restoration of normal body temperature,improvement of lung X-ray and disappearance of lung rales in the observation group were significantly shorter than those in the control group(P<0.05).Before treatment,there was no statistical difference in pulmonary function indicators such as FEV1/FVC,FVC and PEF between the two groups(P>0.05).After treatment,the levels of FEV1/FVC,FVC and PEF in the two groups were significantly higher than those before treatment,and the observation group was significantly higher than the control group(P<0.05).Before treatment,there was no statistical difference in serum tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and high-sensitivity C-reactive protein(hs-CRP)levels between the two groups(P>0.05).After treatment,the levels of serum TNF-α,IL-6 and hs-CRP in both groups were significantly lower than those before treatment,and the observation group was significantly lower than the control group(P<0.05).Conclusion Intravenous infusion of Ambroxol can significantly improve the pulmonary function of patients with severe pneumonia,relieve disease symptoms,and inhibit the body's inflammatory response.These benefits hold promise for a wider application of this procedure clinically.